Vaccines for the prevention of HIV-1 disease

Current Opinion in Immunology

Volumn 13, Issue 4, 2001, Pages 489-494

  Mascola, J R ^a   Nabel, G J ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DNA VACCINE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS VECTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CELLULAR IMMUNITY; DISEASE COURSE; DISEASE TRANSMISSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; INFECTION PREVENTION; MACACA; NONHUMAN; PRIMATE; RETROVIRUS INFECTION; TREATMENT OUTCOME; VACCINATION; VIREMIA; VIRUS RECOMBINANT;

EID: 0035425509     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(00)00246-6     Document Type: Review

References (72)

1. Simian immunodeficiency virus rapidly penetrates the cervicovaginal mucosa after intravaginal inoculation and infects intraepithelial dendritic cells
2. + T helper cells in the cytotoxic T lymphocyte response to HIV-1
3. + T cell responses associated with control of viremia
4. + T lymphocytes
5. Immune control of HIV-1 after early treatment of acute infection
6. Effect of combination antiretroviral therapy on T cell immunity in acute human immunodeficiency virus type 1 infection
7. Containment of simian immunodeficiency virus infection: Cellular immune responses and protection from rechallenge following transient postinoculation antiretroviral treatment
8. Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques
9. Control of SIV rebound through structured treatment interruptions during early infection
10. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys
11. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies
12. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection
13. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies
14. Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160
15. High-titer immune responses elicited by recombinant vaccinia virus priming and particle boosting are ineffective in preventing virulent SIV infection
16. Patterns of viral replication correlate with outcome in simian immuno-deficiency virus (SIV)-infected macaques: Effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara
17. Limited breadth of the protective immunity elicited by simian immunodeficiency virus SIVmne gp160 vaccines in a combination immunization regimen
18. Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol primes for an anamnestic Gag-specific cytotoxic T lymphocyte response and is associated with reduction of viremia after SIV challenge
19. Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV
20. A phase II study of two HIV type 1 envelope vaccines, comparing their immunogenicity in populations at risk for acquiring HIV type 1 infection
21. Cytokine responses to human immunodeficiency virus type 1 (HIV-1) induced by immunization with live recombinant canarypox virus vaccine expressing HIV-1 genes boosted by HIV-1(SF-2) recombinant GP120
22. Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with RGP120
23. A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dual-tropic clade B and C primary isolates
24. Role of dendritic cell targeting in Venezuelan equine encephalitis virus pathogenesis
25. Infection of human dendritic cells by a sindbis virus replicon vector is determined by a single amino acid substitution in the E2 glycoprotein
26. Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles
27. Presentation of SIVgag to monkey T cells using dendritic cells transfected with a recombinant adenovirus
28. Recombinant adenovirus induces maturation of dendritic cells via an NF-κB-dependent pathway
29. Development of a preventive vaccine for Ebola virus infection in primates
30. Replication-deficient recombinant adenoviruses expressing the human immunodeficiency virus Env antigen can induce both humoral and CTL immune responses in mice
31. Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization
32. Factors associated with slow disease progression in macaques immunized with an adenovirus-simian immunodeficiency virus (SIV) envelope priming-gp120 boosting regimen and challenged vaginally with SIVmac251
33. Mucosal immunization of cynomolgus macaques with two serotypes of live poliovirus vectors expressing simian immunodeficiency virus antigens: Stimulation of humoral, mucosal, and cellular immunity
34. Vaccine protection against simian immunodeficiency virus by recombinant strains of herpes simplex virus
35. Recombinant adeno-associated viral vectors mediate long-term transgene expression in muscle
36. Comparison of immunity generated by nucleic acid-, MF59-, and ISCOM-formulated human immunodeficiency virus type 1 vaccines in Rhesus macaques: Evidence for viral clearance
37. Immune responses but no protection against SHIV by gene-gun delivery of HIV-1 DNA followed by recombinant subunit protein boosts
38. Effective induction of simian immunodeficiency virus-specific systemic and mucosal immune responses in primates by vaccination with proviral DNA producing intact but noninfectious virions
39. Protection of Macaca nemestrina from disease following pathogenic simian immunodeficiency virus (SIV) challenge: Utilization of SIV nucleocapsid mutant DNA vaccines with and without an SIV protein boost
40. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine
41. Vaccination of seronegative volunteers with a human immunodeficiency virus type 1 env/rev DNA vaccine induces antigen-specific proliferation and lymphocyte production of beta-chemokines
42. A Rev-independent human immunodeficiency virus type 1 (HIV-1)-based vector that exploits a codon-optimized HIV-1 gag-pol gene
43. Increased expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 gag gene
44. Modulation of antigen-specific humoral responses in rhesus macaques by using cytokine cDNAs as DNA vaccine adjuvants
45. Improving protective immunity induced by DNA-based immunization: Priming with antigen and GM-CSF-encoding plasmid DNA and boosting with antigen-expressing recombinant poxvirus
46. HIV-1 DNA vaccines and chemokines
47. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination
48. Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys
49. Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen
50. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations
51. Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen
52. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine
53. Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination
54. Enhancement of immunodeficiency virus-specific immune responses in DNA-immunized rhesus macaques
55. DNA vaccination with the human immunodeficiency virus type 1 SF162δV2 envelope elicits immune responses that offer partial protection from simian/human immunodeficiency virus infection to CD8(+) T cell-depleted rhesus macaques
56. A phase I trial in HIV negative healthy volunteers evaluating the effect of potent adjuvants on immunogenicity of a recombinant gp120W61D derived from dual tropic R5X4 HIV-1ACH320
57. Evaluation of immune responses induced by HIV-1 gp120 in rhesus macaques: Effect of vaccination on challenge with pathogenic strains of homologous and heterologous simian human immunodeficiency viruses
58. Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140
59. Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous simian/human immunodeficiency virus infection in pigtailed macaques
60. Cross-subtype neutralizing antibodies induced in baboons by a subtype E gp120 immunogen based on an R5 primary human immunodeficiency virus type 1 envelope
61. Cooperative subunit interactions within the oligomeric envelope glycoprotein of HIV-1: Functional complementation of specific defects in gp120 and gp41
62. Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates
63. Variable-loop-deleted variants of the human immunodeficiency virus type 1 envelope glycoprotein can be stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits
64. Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers
65. Expression and characterization of a single-chain polypeptide analogue of the human immunodeficiency virus type 1 gp120-CD4 receptor complex
66. V2 loop glycosylation of the human immunodeficiency virus type 1 SF162 envelope facilitates interaction of this protein with CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies
67. Stable exposure of the coreceptor-binding site in a CD4-independent HIV-1 envelope protein
68. Selection of HIV-specific immunogenic epitopes by screening random peptide libraries with HIV-1-positive sera
69. Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine
70. Vaccination with Rev and Tat against AIDS
71. Vaccination with Tat toxoid attenuates disease in simian/HIV-challenged macaques
72. + cytotoxic T cells after administration of a virus-like particle vaccine in rhesus macaques